Regulatory Momentum: Received positive feedback from the U.S. Food and Drug Administration (“FDA”) following the pre-New Drug Application (“NDA”) meeting minutes for D-PLEX100 in the prevention of ...
Candidates appearing for the Civil Services Examination (CSE) 2026 will get an opportunity to make changes to their ...
KalVista Pharmaceuticals, Inc. is rated a Strong Buy due to EKTERLY's global launch and robust initial sales momentum. Read ...
The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX100 Positive FDA Pre-NDA Feedback Supports Rolling NDA Review- Submission Expected to Begin by the End of the Fir ...
Q4 2025 Earnings Call February 11, 2026 4:30 PM ESTCompany ParticipantsChad Fugure - Vice President of Investor ...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the ...
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health securityStrategic agreement will enable access to Moderna ...
Medincell’s overall ESG rating has been upgraded from C+ to B by ISS, a leading global provider of sustainability ...
SOL-1 Phase 3 superiority trial results remain masked to dateSOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular ...
Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.
Harrow’s ImprimisRx Settles Pending Regulatory Matters with the California Board of Pharmacy ...
Anavex Life Sciences Corp. ("Anavex” or the "Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results